Evofem Biosciences, Inc. (EVFM): Shareholders' Equity
-$74.34M
As of 2025-12-31
-$87.52M
As of 2026-06-30
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$74.34M | n/m | 2026-03-11, Balance as of period end |
| 2024-12-31 | -$71.26M | n/m | 2026-03-11, Balance as of period end |
| 2023-12-31 | -$66.51M | n/m | 2025-03-24, Balance as of period end |
| 2022-12-31 | -$71.80M | n/m | 2024-03-27, Balance as of period end |
| 2021-12-31 | -$104.31M | n/m | 2023-04-27, Balance as of period end |
| 2020-12-31 | $1.35M | -91.4% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $15.64M | n/m | 2021-03-04, Balance as of period end |
| 2018-12-31 | -$23.36M | n/m | 2020-03-12, Balance as of period end |
| 2017-12-31 | -$289.55M | n/m | 2019-03-01, Balance as of period end |
| 2016-12-31 | $11.91M | -50.0% | 2018-02-26, Balance as of period end |
| 2015-12-31 | $23.81M | -63.5% | 2018-02-26, Balance as of period end |
| 2014-12-31 | $65.25M | n/m | 2017-03-23, Balance as of period end |
| 2013-12-31 | -$56.69M | n/a | 2016-03-29, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | -$74.34M | n/m |
| Scynexis Inc (SCYX) | 2025-12-31 | $49.38M | -10.4% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | -$37.28M | n/m |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $22.81M | -20.9% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $683.43M | -9.8% |
| Alumis Inc. (ALMS) | 2025-12-31 | $301.30M | +15.8% |
| uniQure N.V. (QURE) | 2025-12-31 | $198.90M | n/m |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $306.13M | -28.6% |
| Celularity Inc (CELU) | 2025-12-31 | -$38.06M | n/m |
Compare EVFM, SCYX, CASIF, SLGL side by side · Screen every company in Pharmaceutical Preparations ↗